

Special Issue

Germline Pharmacogenetics of Cancer Treatment

Message from the Guest Editor

The patient's inherited germline genome can be important for determining how they process (pharmacokinetics) or respond to (pharmacodynamics) cancer treatment. This Special Issue will describe the current status of germline pharmacogenetics in oncology and report novel findings in this field. Original research articles can describe the discovery, replication, or implementation of germline cancer pharmacogenetics associations, including associations with drug pharmacokinetics, treatment efficacy or toxicity. Review articles describing the current state of knowledge of pharmacogenetic associations in oncology or their clinical implementation are also welcome.

Guest Editor

Dr. Daniel L. Hertz

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church St. Ann Arbor, MI 48109-1065

Deadline for manuscript submissions

closed (28 February 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/51869

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)